Raphael Pharmaceutical appoints new CFO amid departures
Raphael Pharmaceutical Inc. reports several senior leadership changes.
Rhea-AI Filing Summary
Raphael Pharmaceutical Inc. reports several senior leadership changes. Ajay Kumar Dhadha voluntarily resigned as Chairman of the Board and Director, effective June 30, 2026. The company states his resignation was not due to any disagreement regarding operations, policies, practices, financial reporting, management, or the Board.
Guy Ofir voluntarily resigned as Chief Financial Officer, General Counsel, and Director, effective July 16, 2026, also described as not resulting from any such disagreement. Effective July 16, 2026, Uri Tadelis was appointed as the company’s Chief Financial Officer.
Positive
- None.
Negative
- Multiple senior departures: The company reports the resignation of its Chairman and its Chief Financial Officer/General Counsel, resulting in several board and executive role changes within a short period.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Emerging growth company, Chief Financial Officer, Board of Directors, General Counsel
4 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Chief Financial Officer financial
"appointed Mr. Uri Tadelis as its Chief Financial Officer"
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
Board of Directors regulatory
"resigned from his positions as Chairman of the Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
General Counsel regulatory
"resigned from his positions as Chief Financial Officer, General Counsel"
A general counsel is the chief lawyer of an organization, responsible for overseeing all legal matters and ensuring the company complies with laws and regulations. Think of them as the organization's legal advisor or navigator, helping to prevent legal problems before they happen. Their role matters to investors because they help protect the company from legal risks that could impact its success and value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership changes did Raphael Pharmaceutical Inc. (RAPH) disclose?
Raphael Pharmaceutical Inc. reported that Ajay Kumar Dhadha resigned as Chairman and Director, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director, with Uri Tadelis appointed as the new Chief Financial Officer.
When did the chairman of Raphael Pharmaceutical Inc. (RAPH) resign?
The chairman, Ajay Kumar Dhadha, resigned as Chairman of the Board and Director effective June 30, 2026. His resignation is described as voluntary and not due to any disagreement with the company’s operations, policies, practices, financial reporting, management, or Board.
When did Raphael Pharmaceutical Inc. (RAPH) CFO and General Counsel resign?
Raphael Pharmaceutical Inc. states that Guy Ofir voluntarily resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. The company notes that his resignation was not the result of any disagreement on operations, policies, practices, financial reporting, management, or Board matters.
Who is the new Chief Financial Officer of Raphael Pharmaceutical Inc. (RAPH)?
Effective July 16, 2026, Raphael Pharmaceutical Inc. appointed Uri Tadelis as its Chief Financial Officer. His appointment follows the voluntary resignation of former CFO and General Counsel Guy Ofir from his roles with the company and its Board.
Did the resignations at Raphael Pharmaceutical Inc. (RAPH) involve any disagreements?
The company states that the resignations of Ajay Kumar Dhadha and Guy Ofir were not the result of disagreements regarding its operations, policies, practices, financial reporting, management, or Board of Directors, characterizing the departures as voluntary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
